TrialsWest

Current Studies

Breakthrough treatment starts here. Browse our open clinical trials across
Western Australia and find one that's right for you.

Filters
Filters
    Show (14)
    Cancel

    • Recruiting

      Respiratory

      PROPEL-IPF

      A Phase 2 clinical trial evaluating an oral investigational medication for people with idiopathic pulmonary fibrosis (IPF).

      Condition

      Idiopathic Pulmonary Fibrosis

      Study Duration

      up to 36 weeks

      Location

      Spearwood

      Read more: PROPEL-IPF

    • Closed

      Respiratory

      Bronchiectasis | AIRTIVITY™ 

      Study testing a new oral medication for bronchiectasis to reduce flare-ups and improve symptoms.

      Condition

      Bronchiectasis

      Study Duration

      1.5 years

      Location

      Spearwood

      Read more: Bronchiectasis | AIRTIVITY™ 

    • Recruiting

      Respiratory

      Bronchiectasis | CSL787_2001

      The study aims to determine whether an inhalant medication can delay or reduce lung flare‑ups, improve quality of life, and remain safe and well tolerated.

      Condition

      Non-cystic Fibrosis Bronchiectasis

      Study Duration

      12 months

      Location

      Osborne Park

      Read more: Bronchiectasis | CSL787_2001

    • Recruiting

      Metabolic

      MASH | INI-822-001

      This early study is testing a new drug in people with a liver condition to check if it’s safe and how well people tolerate it. It also looks at how the drug moves through the body and what effects it has, using gradually increasing doses.

      Condition

      Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH)

      Study Duration

      12 weeks

      Location

      Mandurah

      Read more: MASH | INI-822-001

    • Recruiting

      Respiratory

      COPD | PRESTO

      This study is testing different doses of a new medication to see how safe it is and how well it works compared to a placebo in people with moderate to very severe COPD.

      Condition

      Chronic Obstructive Pulmonary Disease (COPD)

      Study Duration

      6 months

      Location

      Osborne Park

      Read more: COPD | PRESTO

    • Recruiting

      Metabolic

      MASH | SYNERGY-Outcomes

      The main goal of this study is to see if two different drugs can protect people with a specific type of high-risk fatty liver disease from developing severe, life-threatening liver problems.

      Condition

      Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH)

      Study Duration

      2.5 years

      Location

      Osborne Park

      Read more: MASH | SYNERGY-Outcomes

    • Recruiting

      Gastroenterology

      Haemochromatosis | FERROCLEAR

      This study is testing a new medicine called Vamfeport in adults with a genetic condition that causes the body to absorb too much iron

      Condition

      Hereditary Haemochromatosis

      Study Duration

      12 months

      Location

      Osborne Park

      Read more: Haemochromatosis | FERROCLEAR

    • Recruiting

      Respiratory

      COPD | THESEUS

      A study evaluating the efficacy, safety, and tolerability of a new drug in adults with inadequately controlled Chronic Obstructive Pulmonary Disease (COPD).

      Condition

      Chronic Obstructive Pulmonary Disease (COPD)

      Study Duration

      up to 1 year

      Location

      Osborne Park

      Read more: COPD | THESEUS

    • Recruiting

      Respiratory

      COPD | VIGILANT

      A clinical research study to evaluate an investigational drug as an add-on treatment for Chronic Obstructive Pulmonary Disease (COPD)

      Condition

      Chronic Obstructive Pulmonary Disease (COPD)

      Study Duration

      up to 3 years

      Location

      Mandurah

      Read more: COPD | VIGILANT

    • Recruiting

      Liver - Metabolic

      MASH | SF-CSP-002

      The purpose of this study is to test the effectiveness and safety of the investigational medication in the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in at risk adults.

      Condition

      Metabolic Dysfunction-Associated Steatohepatitis (MASH)

      Study Duration

      34 weeks

      Location

      Spearwood, Osborne Park and Mandurah

      Read more: MASH | SF-CSP-002

    • Recruiting

      Cardiovascular

      Cardiovascular | PREVENT_HF

      Heart Failure D697300001 Prevent-HF Study

      Condition

      Heart Failure

      Study Duration

      Up to 2 years

      Location

      Osborne Park

      Read more: Cardiovascular | PREVENT_HF

    • Closed

      Otolaryngology

      Chronic Rhinosinusitis | CEREN-2

      EFC18419 / Ceren 2

      Condition

      Chronic Sinusitis

      Study Duration

      Up to 76 weeks

      Location

      Spearwood

      Read more: Chronic Rhinosinusitis | CEREN-2

    • Closed

      Respiratory

      CALM-2 | BUS-P3-02

      BUS-P3-02 / CALM-2 Study

      Condition

      Chronic Cough

      Study Duration

      Up to 71 weeks

      Location

      Spearwood

      Read more: CALM-2 | BUS-P3-02

    • Closed

      Respiratory

      COPD | AER-01-002

      A Phase 2a, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fexlamose (AER-01) Inhalation Solution in the Treatment of Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease

      Condition

      Chronic Obstructive Pulmonary Disease (COPD)

      Study Duration

      Up to 10 weeks

      Location

      Spearwood & Osborne Park

      Read more: COPD | AER-01-002

    Participate in a Trial
    Participate in a Trial
    Scroll to Top
    Secret Link